Hodgkin Lymphoma: Complete ICD-11 Coding Guide

Overview

Hodgkin Lymphoma is a malignant neoplasm of the lymphatic system that represents approximately 10% of all lymphomas. This disease is characterized by the presence of specific tumor cells (Reed-Sternberg cells) within an abundant inflammatory infiltrate. Correct coding using the 2B30 code from ICD-11 is essential for clinical documentation, epidemiological research, and therapeutic planning.

With cure rates exceeding 85% when diagnosed early, Hodgkin Lymphoma is considered one of the malignant neoplasms with the best prognosis. The disease presents a bimodal age distribution, primarily affecting young adults (20-30 years) and elderly individuals (over 55 years). Precise understanding of code 2B30 and its subcategories allows for adequate case tracking and international data comparisons.

This comprehensive guide addresses the practical aspects of coding Hodgkin Lymphoma according to ICD-11, including diagnostic criteria, differentiation of subcategories, and detailed clinical examples.

ICD-11 Code

Code: 2B30 Category: Hodgkin lymphoma Chapter: 02 - Neoplasms Subcategories: 2 specific codes

The code 2B30 is part of the neoplasms chapter of ICD-11 and encompasses all variants of Hodgkin lymphoma. For greater diagnostic precision, the code has two main subcategories:

• 2B30.0: Hodgkin lymphoma with nodular lymphocyte predominance
• 2B30.1: Classical Hodgkin lymphoma

Subcategories and Classification

2B30.0 - Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Represents approximately 5% of Hodgkin lymphoma cases. It is characterized by:

Histological Features:

• LP cells (lymphocytic and histiocytic) in nodular pattern
• Background rich in small lymphocytes
• Absence of classic Reed-Sternberg cells

Immunophenotyping:

• CD20 positive
• CD15 negative
• CD30 negative

Clinical Presentation:

• Predominates in young men
• Localized disease in early stages
• Involvement of cervical, axillary, or inguinal lymph nodes
• Absence of significant mediastinal mass
• Better prognosis, but with tendency for late relapses

2B30.1 - Classical Hodgkin Lymphoma

Represents 95% of cases and encompasses four histological subtypes:

Subtypes:

1. Nodular sclerosis (60-70% of cases)

   • Most common in young women
   • Frequent mediastinal mass
   • Presence of fibrosis bands

2. Mixed cellularity (20-25% of cases)

   • Equal distribution between sexes
   • Numerous Reed-Sternberg cells
   • Association with HIV in some cases

3. Lymphocyte-rich (5% of cases)

   • Good prognosis
   • Very few Reed-Sternberg cells
   • Background rich in small lymphocytes

4. Lymphocyte depletion (<5% of cases)

   • Worse prognosis
   • Numerous Reed-Sternberg cells
   • Few background lymphocytes

Classical Immunophenotyping:

• CD30 positive
• CD15 positive
• CD20 negative
• CD3 negative

Diagnostic Criteria

Clinical Criteria

Typical Presentation:

• Painless peripheral lymphadenopathy (60-80% of cases)
• Cervical or supraclavicular location predominant
• Mediastinal mass (50-60% of cases)
• B symptoms in 30-40% of patients:
  • Persistent fever (>38°C)
  • Profuse night sweats
  • Weight loss >10% in 6 months

Additional Symptoms:

• Generalized pruritus (10-15% of cases)
• Cough and dyspnea (if mediastinal mass)
• Fatigue and general malaise

Laboratory Criteria

Complete Blood Count:

• Normocytic normochromic anemia (30% of cases)
• Leukocytosis with lymphopenia in advanced disease
• Eosinophilia (15-20% of cases)
• Reactive thrombocytosis

Inflammatory Markers:

• ESR frequently elevated (>50 mm/h)
• Elevated C-reactive protein
• LDH may be increased
• Hypoalbuminemia in advanced disease

Imaging Criteria

Essential Examinations:

• Contrast-enhanced CT of neck, chest, abdomen, and pelvis
• PET-CT with 18F-FDG (gold standard for staging)
• Chest radiograph (mediastinal widening)
• MRI in selected cases (CNS or bone involvement)

Characteristic Findings:

• Lymphadenopathy in multiple chains
• Increased uptake on PET-CT
• Anterior mediastinal mass
• Pattern of contiguous progression

Histopathological Criteria

Excisional Biopsy:

• Mandatory for definitive diagnosis
• Superior to fine needle aspiration
• Allows complete architectural evaluation

Microscopic Findings:

• Reed-Sternberg cells or variants (0.1-10% of cellularity)
• Rich and varied inflammatory infiltrate
• Lymphocytes, eosinophils, neutrophils, histiocytes
• Characteristic architectural pattern by subtype

Essential Immunohistochemistry:

• CD30, CD15 (classical)
• CD20, CD79a (nodular)
• PAX5, CD45
• EBV (in selected cases)

When to Use Code 2B30

Scenario 1: Cervical Lymphadenopathy with Histological Confirmation

Case:

• 28-year-old patient, painless cervical mass for 3 months
• Progressive growth from 2 to 4 cm
• Biopsy: Reed-Sternberg cells CD30+/CD15+
• PET-CT: uptake in bilateral cervical chains

Coding: 2B30.1 (Classical Hodgkin lymphoma)

Rationale: Histopathological confirmation with immunophenotyping characteristic of the classical subtype.

Scenario 2: Mediastinal Mass with B Symptoms

Case:

• 25-year-old woman
• Dry cough, evening fever, 8 kg weight loss in 2 months
• CT: anterior mediastinal mass of 12 cm
• Biopsy by mediastinoscopy: nodular sclerosis

Coding: 2B30.1 (Classical Hodgkin lymphoma)

Rationale: Histological pattern of nodular sclerosis confirmed, most common subtype of classical Hodgkin lymphoma.

Scenario 3: Localized Disease in Young Adult

Case:

• 32-year-old man
• Enlarged axillary lymph node, asymptomatic
• Biopsy: nodular pattern with LP cells CD20+/CD30-
• Staging: IA

Coding: 2B30.0 (nodular lymphocyte predominance)

Rationale: Immunophenotyping characteristic of the nodular subtype, localized disease, absence of B symptoms.

Scenario 4: Disseminated Disease

Case:

• 65-year-old patient
• Generalized lymphadenopathy and splenomegaly
• Biopsy: mixed cellularity with numerous Reed-Sternberg cells
• PET-CT: multiple nodal and splenic sites

Coding: 2B30.1 (Classical Hodgkin lymphoma)

Rationale: Mixed cellularity subtype confirmed, advanced disease with splenic involvement.

When NOT to Use Code 2B30

Exclusion Situations

❌ Diffuse Large B-Cell Lymphoma

• If biopsy shows B-cell proliferation without Reed-Sternberg cells
• Use specific code for non-Hodgkin lymphoma

❌ Leukemia with Circulating Blasts

• If complete blood count shows blasts in peripheral blood
• Consider acute leukemia codes

❌ Clinical Suspicion Only

• Without histopathological confirmation
• Use symptom code or "suspected neoplasm"

❌ Langerhans Cell Histiocytosis

• Specific histological diagnosis
• Use appropriate code for histiocytic neoplasms

Differentiation of Related Codes

2B30 vs Non-Hodgkin Lymphomas

Hodgkin Lymphoma (2B30):

• Rare tumor cells (0.1-10%)
• Abundant inflammatory background
• CD30+ / CD15+ (classic)
• Contiguous progression of lymph nodes

Non-Hodgkin Lymphomas:

• Predominant proliferation of neoplastic lymphoid cells
• Non-contiguous dissemination pattern
• Variable immunophenotyping

2B30 vs Acute Leukemias

Hodgkin Lymphoma (2B30):

• Primary lymph node involvement
• Absence of circulating blasts
• Characteristic Reed-Sternberg cells

Acute Leukemias:

• Primary bone marrow involvement
• Blasts in peripheral blood
• Frequent pancytopenia

Quick Reference Table

| Aspect | Details | |---------|----------| | Code | 2B30 | | Category | Hodgkin Lymphoma | | Chapter | 02 - Neoplasms | | Subcategories | 2 (2B30.0, 2B30.1) | | Typical Age | Bimodal: 20-30 and >55 years | | Primary Location | Lymph nodes (cervical, mediastinal) | | Classic Markers | CD30+, CD15+ | | Prognosis | Excellent (>85% 5-year survival) | | B Symptoms | 30-40% of cases |

Complete Practical Example

Detailed Clinical Case

Identification:

• Male, 26 years old, university student

Chief Complaint:

• "Lump" in the neck for 2 months

History of Present Illness:

• Right cervical lymph node, initially 2 cm, now 4 cm
• Progressive growth
• Painless, firm consistency, mobile
• Afternoon fever (38-38.5°C) for the past 3 weeks
• Intense night sweats with need to change clothes
• Unintentional weight loss of 6 kg in the last month
• Denies cough, dyspnea, or other symptoms

Physical Examination:

• Right cervical lymph node: 4x3 cm, painless, firm, mobile
• Right supraclavicular lymph node: 2 cm
• Absence of hepatosplenomegaly

Laboratory Tests:

• Hemoglobin: 11.2 g/dL (mild anemia)
• Leukocytes: 12,000/mm³ with relative lymphopenia
• ESR: 68 mm/h (markedly elevated)

Imaging Studies:

• Chest CT: superior mediastinal mass of 7 cm

Excisional Biopsy:

• Effaced nodal architecture
• Binucleated and multinucleated Reed-Sternberg cells
• Background of lymphocytes, eosinophils, and fibrosis
• Immunohistochemistry: CD30+, CD15+, CD20-, CD3-

Diagnosis: Classical Hodgkin lymphoma, nodular sclerosis subtype

Staging:

• PET-CT: uptake in bilateral cervical, supraclavicular, and mediastinal nodes
• Stage IIB (involvement of two nodal regions on the same side of the diaphragm with B symptoms)

Step-by-Step Coding

1. Criteria Analysis:

• ✅ Histopathological confirmation: Reed-Sternberg cells present
• ✅ Typical immunophenotyping: CD30+/CD15+
• ✅ Compatible clinical presentation: B symptoms present
• ✅ Characteristic nodal involvement

2. Code Selection: 2B30.1 - Classical Hodgkin lymphoma

3. Justification: The biopsy confirms classical Hodgkin lymphoma with nodular sclerosis pattern. The CD30+/CD15+ immunophenotyping differentiates it from the nodular subtype (2B30.0), which would be CD20+/CD30-. The clinical pattern with mediastinal mass and B symptoms is characteristic of the classical subtype.

4. Complementary Codes:

• Staging: IIB
• Location: cervical and mediastinal
• B symptoms: present

Required Documentation

Mandatory Checklist

• [ ] Histopathological report with description of Reed-Sternberg cells
• [ ] Complete immunohistochemistry (CD30, CD15, CD20)
• [ ] Imaging staging (PET-CT or CT)
• [ ] Documentation of B symptoms (if present)
• [ ] Complete blood count and inflammatory markers
• [ ] Specification of histological subtype

Essential Information in Medical Record

Clinical Data:

• Location of involved lymph nodes
• Presence or absence of B symptoms
• Size of tumor masses
• Patient performance status

Laboratory Data:

• Complete blood count with differential
• ESR and CRP
• LDH
• Hepatic and renal function

Histopathological Data:

• Type of sample (excisional biopsy vs core)
• Detailed morphological description
• Complete immunohistochemistry results
• Specific histological subtype

Frequently Asked Questions

What is the difference between 2B30.0 and 2B30.1?

The main difference lies in histology and immunophenotyping:

2B30.0 (Nodular Predominance):

• LP cells in nodular pattern
• CD20+, CD30-, CD15-
• 5% of cases
• Better prognosis, late relapses
• More localized disease

2B30.1 (Classical):

• Reed-Sternberg cells
• CD30+, CD15+, CD20-
• 95% of cases
• Four histological subtypes
• Mediastinal mass more common

Is it always necessary to specify the subtype?

Ideally yes. Specification of the subtype (2B30.0 or 2B30.1) provides important prognostic and therapeutic information. However, the code 2B30 can be used temporarily while awaiting confirmation of the specific subtype.

Can I use 2B30 in case of relapse?

Yes. The code 2B30 remains appropriate for documenting relapse of the same disease. Additionally, it should be specified that this is a relapse and include data on prior treatment.

How do I code if there is comorbid ADHD?

Comorbidities should be coded separately with their specific codes. The code 2B30 is used for Hodgkin Lymphoma, and additional codes are included for other coexisting conditions.

Is this code used in all countries?

Yes. ICD-11 is an international standard of the World Health Organization, used globally for coding diseases and health conditions.

Practical Tips for Coding

For Physicians

1. Always request excisional biopsy (not just needle biopsy)
2. Ensure complete immunohistochemistry in the request
3. Clearly document the presence or absence of B symptoms
4. Specify complete staging
5. Maintain detailed record of clinical findings

For Coders

1. Verify if the report specifies the histological subtype
2. Confirm presence of immunohistochemistry in the report
3. Use 2B30.0 or 2B30.1 as specified
4. Pay attention to complementary codes (staging)
5. Document whether it is initial diagnosis or recurrence

For Pathologists

1. Always specify whether it is nodular (2B30.0) or classic (2B30.1)
2. Include immunohistochemistry in the standard report
3. Detail the subtype of classic when possible
4. Mention relevant prognostic characteristics

Resources and References

Official Documentation

• World Health Organization (WHO). ICD-11 - International Classification of Diseases, 11th Revision. 2024.
• ICD-11 Browser: ICD-11 Browser

Scientific Literature

• Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574-83.
• Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv19-iv29.
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-132.

Clinical Guidelines

• National Comprehensive Cancer Network (NCCN) Guidelines for Hodgkin Lymphoma
• European Society for Medical Oncology (ESMO) Clinical Practice Guidelines
• American Society of Clinical Oncology (ASCO) Guidelines

---

Article updated according to ICD-11 version 2024-01 Technical content developed for healthcare professionals